SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-24-003430
Filing Date
2024-06-13
Accepted
2024-06-13 16:23:55
Documents
14
Period of Report
2024-06-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_061324.htm   iXBRL 8-K 34641
2 EXHIBIT 10.1 exh_101.htm EX-10.1 132522
  Complete submission text file 0001171843-24-003430.txt   372755

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bcrx-20240612.xsd EX-101.SCH 3030
4 XBRL LABEL FILE bcrx-20240612_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE bcrx-20240612_pre.xml EX-101.PRE 22369
17 EXTRACTED XBRL INSTANCE DOCUMENT f8k_061324_htm.xml XML 3670
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 241041563
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)